News | Cardiovascular Business | January 19, 2023

Shockwave Medical Announces Agreement to Acquire Neovasc

Neovasc’s Innovative Reducer System will target the estimated $5 billion refractory angina market

Neovasc’s Innovative Reducer System will target the estimated $5 billion refractory angina market

January 19, 2023 — Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc., a company focused on the minimally invasive treatment of refractory angina. 

The Neovasc Reducer System is a first-of-its-kind technology to address refractory angina. Refractory angina is a chronic condition in which a patient suffers chest pain that cannot be controlled by conventional therapies. It is estimated that each year, in the U.S. and the E.U. alone, up to 300,000 new patients with obstructive coronary disease who are ineligible for conventional revascularization experience refractory angina, despite guideline-directed medical therapy. In addition, it is estimated that up to another 500,000 new patients present with angina and non-obstructive coronary artery disease (ANOCA) in the U.S. and the E.U. each year. The Neovasc Reducer System has been granted Breakthrough Device designation by the FDA, is CE-marked and is currently enrolling patients in the COSIRA-II study, a randomized clinical trial being conducted under an Investigation Device Exemption intended to support U.S. FDA approval for patients with coronary obstructive refractory angina. 

“Refractory angina is a debilitating condition without an effective therapy that impacts millions of patients,” said Gregg W. Stone, MD, FACC, MSCAI, Principal Investigator of COSIRA-II, Director of Academic Affairs for the Mount Sinai Heart Health System, and Professor of Medicine (Cardiology) and of Population Health Sciences and Policy. “The ongoing COSIRA-II randomized trial has been designed to definitively demonstrate that the Reducer is superior to a sham control for these patients, offering the potential to change the lives of these patients who are desperate for a solution for their refractory angina.” 

“Our team at Shockwave has proven that we excel at developing products and markets for large, underserved patient populations and commercializing innovative solutions for these patients. We believe the Reducer is an excellent fit for Shockwave as it enables us to apply our capabilities to address another large, unmet need within cardiology – refractory angina,” said Doug Godshall, President and Chief Executive Officer of Shockwave. “The timing is ideal as there will be no distraction to our U.S. sales organization in the near term and, as we did with C2, our coronary device, we expect to refine our commercialization approach and begin the development of international markets in advance of U.S. approval. This transaction supports our commitment to drive growth through innovation and we are excited for the potential to bring even more solutions to our customers and the patients they serve with the Reducer System.” 

Terms of the Neovasc Agreement

Upon the closing of the transaction, Shockwave Medical will acquire all outstanding Neovasc shares for an upfront cash payment of $27.25 per share, corresponding to an enterprise value of approximately $100 million, inclusive of certain deal-related costs. Neovasc shareholders will also receive a potential deferred payment in the form of a non-tradable contingent value right (CVR) entitling the holder to receive up to an additional $12 per share in cash if certain regulatory milestones are achieved. The upfront cash consideration represents a premium of 27% and 68% to the closing price and 30-day VWAP, respectively, of Neovasc’s common shares on the Nasdaq Capital Market on January 13, 2023. 

The transaction will be effected by way of a court-approved plan of arrangement pursuant to the Canada Business Corporations Act, and is subject to customary closing conditions, including requisite Neovasc shareholder approval. Shockwave expects to complete the transaction in the first half of 2023. 

The Board of Directors of Neovasc, acting on the unanimous recommendation of a special committee comprised of independent directors and after having received an opinion from its financial advisor to the effect that the consideration to be received by Neovasc shareholders pursuant to the plan of arrangement is fair from a financial point of view, has unanimously approved the arrangement. Directors and executive officers of Neovasc and related parties, holding an aggregate of approximately 9.23% of the Neovasc shares currently outstanding (on a non-diluted basis) have entered into support and voting agreements with Shockwave. 

For more information: www.shockwavemedical.com 

Related Content: 

Shockwave Intravascular Lithotripsy-assisted TMVR Shows Promise for Patients with Severe Stenosis and Regurgitation 

Shockwave Medical Initiates All-Female Coronary IVL Study 

Disrupt PAD III Trial Demonstrates Safety and Effectiveness of Intravascular Lithotripsy for Peripheral Artery Calcification 

Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference Preview 

Medtronic Intrepid Transcatheter Mitral Valve Successfully Uses Transfemoral Delivery 

Late-Breaking Data from PROTECTED TAVR Trial Demonstrate Reduced Risk of Disabling Stroke, Low Complication Rate with SENTINEL Cerebral Protection System 


Related Content

News | Structural Heart

February 6, 2023 — University of Virginia researchers and their collaborators have identified genes that play key roles ...

Home February 06, 2023
Home
News | Structural Heart

January 19, 2023 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the company's latest ...

Home January 19, 2023
Home
News | Structural Heart

December 13, 2022 — Edwards Lifesciences Corporation announced that one-year results on patients treated in the single ...

Home December 13, 2022
Home
News | Structural Heart

December 2, 2022 — Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market ...

Home December 02, 2022
Home
News | Structural Heart

November 30, 2022 — Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market ...

Home November 30, 2022
Home
News | Structural Heart

November 30, 2022 — Medtronic’s newest generation self-expanding, transcatheter aortic valve replacement (TAVR) system ...

Home November 30, 2022
Home
News | Structural Heart

September 26, 2022 — Medtronic plc, a global leader in medical technology, announced U.S. Food and Drug Administration ...

Home September 26, 2022
Home
News | Structural Heart

September 20, 2022 — Results of the first randomized controlled trial to directly compare two contemporary transcatheter ...

Home September 20, 2022
Home
News | Structural Heart

September 17, 2022 — Abbott today announced data from five late-breaking presentations showing the benefits of its ...

Home September 17, 2022
Home
News | Structural Heart

September 17, 2022 — Medtronic today announced findings from its Pathological Study of Hypo-Attenuated Leaflet ...

Home September 17, 2022
Home
Subscribe Now